Ant Group’s ESG strategy aims to support 100 million SMEs by 2030
1.6.2022 06:07:00 EEST | Business Wire | Press release
Ant Group, a global technology provider, today announced its Environmental, Social and Governance (ESG) strategy as part of its latest sustainability report. The ESG strategy, which lays out Ant Group’s sustainable development objectives by 2030, will be implemented across all aspects of the Company’s operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531006112/en/
Four pillars of Ant Group’s ESG strategy and objectives by 2030 (Graphic: Business Wire)
Ant Group’s ESG strategy is focused around four pillars: Digital Inclusion, Green and Low-carbon Development, Open Ecosystem, and Technological Innovation. Each of the pillars has a corresponding sustainable development objective by 2030:
- Digital Inclusion: support 100 million small and micro-sized enterprises (SMEs) and serve communities globally
- Green and Low-carbon Development: achieve corporate carbon neutrality and support business partners and the general public to significantly reduce their carbon footprint
- Open Ecosystem: continue to provide a safe, trusted, diversified and open ecosystem to drive common development with partners
- Technological Innovation: continue to invest in core technology research and development to provide world-leading technological products and services
"We believe these are the most important pillars for Ant Group to achieve sustainable growth in a future-facing, responsible, and responsive manner,” wrote Eric Jing, Ant Group’s Chairman and CEO, in the sustainability report. ”This framework will guide Ant Group’s value creation and sustainable development in the future.”
Ant Group formulated its ESG strategy based on a comprehensive assessment of changing macro environment and policy trends, its own development strengths, and inputs from the Company’s stakeholders, including customers, users, employees, partners and governments. The ESG strategy was finalized after extensive management discussions and a detailed Board review.
After solicitating feedback from stakeholders, Ant Group defined 19 material issues for its ESG strategy, ranging from “responsible products and services,” “facilitating industry-wide carbon neutrality,” “cutting-edge technology discovery and R&D” and “transparency & risk management.”
To provide organizational support to effectively implement the ESG strategy, the Company’s Board of Directors has approved the establishment of an ESG sustainable development committee, comprised of a subset of the Board, responsible for decision-making supervision, risk management and policy making. The Company is setting up an advisory committee consisting of internal and external ESG experts to provide input and support. Ant Group has also set up an ESG sustainable development leadership team, led by the CEO and the Chief Sustainability Officer, as well as working groups for each of the 19 ESG material issues.
“Our ESG strategy originated from our own long-term needs and was not a spur-of-the-moment decision. The pursuit of sustainable development has been inherent in every step of our journey and is not designed to cater to short-term trends, but rather a necessary driver to realize our vision to be a good company that will last for at least 102 years,” added Mr. Jing. “A good company is never independently defined. We will listen to the opinions and suggestions from all parties with an open mind and welcome supervision and guidance from all of our stakeholders.”
As part of its “Technological Innovation” pillar, Ant Group has been increasing its R&D investments, which grew at an annual rate of more than 39% for three consecutive years (2018-2021), with total R&D spending in 2021 exceeding RMB 18.8 billion (approx. USD 2.77 billion). These investments enabled the Company to continuously turn technological breakthroughs into innovative, inclusive and reliable products and services to support the digital transformation of industries and better anticipate the evolving needs of an increasingly digital global economy. In 2021, MYbank, an Ant Group associate and an online SME bank, leveraged digital technology to deliver convenient, accessible and responsible collateral-free financing services to 45 million SMEs.
In February 2022, Ant Group was recognized as a Top 100 Global Innovator™ 2022 by Clarivate™. This prestigious annual list identifies global companies and institutions that contribute new ideas, solve problems and create new economic value.
Since 2017, three years after Ant Group’s establishment, the Company has steadily introduced and advanced its ESG assessment framework and published an annual sustainability report, compiled according to the Global Reporting Initiative standards. These reports, including the latest 2021 edition with the Company’s ESG strategy, can be found on Ant Group’s website (Chinese only for now, English edition will be online in the coming weeks).
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006112/en/
Contact information
Media Inquiries
Le SHEN
Shenle.sl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom